Skip to main content
. Author manuscript; available in PMC: 2014 May 6.
Published in final edited form as: Bioconjug Chem. 2012 Dec 26;24(1):4–8. doi: 10.1021/bc300095m

Figure 4.

Figure 4

H-gemcitabine has greater efficacy than gemcitabine in treating tumors in vivo. a) Tumor bearing nude mice were injected with either H-gemcitabine (25 mg/kg of gemcitabine equivalents, 95 μmol/kg) or free gemcitabine (100 mg/kg, 380 μmol/kg) on days 0, 3, 6, and 9. Tumors treated with H-gemcitabine have minimal growth, whereas tumors treated with gemcitabine increase in size (mean ± STD, n=5, *p≤0.05 vs gemcitabine). b) Tumor bearing mice have a higher survival rate at 30 days after treatment with H-gemcitabine (80%) than with free gemcitabine (13%). The Survival curve was generated by determining the percentage of mice surviving with respect to the start of the study. Log-rank test was performed to determine statistical significance between the survival curves (*p < 0.05, n = 10 for H-gemcitabine and n = 9 for gemcitabine).